+ 49 (0) 2204 2918806
Manufacturer: GlobalData

PharmaPoint: Postmenopausal Vaginal Atrophy - US Drug Forecast And Market Analysis To 2022

SKU:GDHC176CFR / 378560
Publication Date:31.07.2013
Language version:English
Report Type:Zukunftsanalyse
Lieferzeit:2-3 Tage
Nr of pages:88 pages
Rating:Für diese Studie liegt keine Bewertung vor.
$4,995.00   *
* Click here to switch the currency you want to pay in.
More about this report
Table of Contents
Other relevant reports
Our guarantee

Numbers and facts for this report

- Overview of PVA including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the US PVA market.

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for PVA
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in the US

Content of the report

Although the postmenopausal vaginal atrophy (PVA) market has experienced anemic growth over the past decade, it is expected to undergo a considerable change between 2012 and 2022. This market has historically had a large untreated population due to: low diagnosis rates, safety issues with the existing therapies, and poor patient compliance. Since the mainstay estrogen-based therapies are associated with causing elevated risk for breast cancer, endometrial cancer, and stroke, many women go untreated.

During the forecast period, the primary driver for market growth will be the expected launch of two first-in-class non-estrogen therapies - namely, Osphena and Vaginorm. Growth in this market will be somewhat stymied early in the forecast period by the patent expiry of Pfizer’s blockbuster Premarin family of drugs by 2014.